Any buyout should be north of 70 billion. Eli Lilly could do it easily. We are not in a hurry. The EMA is working. With approval we start trials in Rhett, Parkinsons, dementia, fragil x, and more. Revenue stream in five years with prophylactic use?
Market Data 
Markets 
AI
